UnknownPhase 4

Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy

China80 participantsStarted 2010-04

Plain-language summary

The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * hepatocellular carcinoma * treated with transcatheter arterial chemoembolization (TACE) * HBVDNA \> 10\^3copies/mL, including alanine aminotransferase (ALT) normal patient * expected survive time \> 1 year * HBV marker positive (anyone of HbsAg, HbsAb, HbeAg, HbeAb and HbcAb) Exclusion Criteria: * antiviral therapy history * alanine aminotransferase (ALT) \>400 U/L * serum total bilirubin \> 50 μmol/L * HBVDNA \> 10\^9copies/mL * extrahepatic metastasis or main portal vein embolus * apparent cardiac or pulmonary dysfunction * liver function: Child B or Child C * HCV infection

What they're measuring

Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Timeframe: 6 months

Trial details

NCT IDNCT01102335

SponsorFudan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-12

Contact for this trial

jinglin xia, MD

xia.jinglin@zs-hospital.sh.cn

View on ClinicalTrials.gov More Hepatocellular Carcinoma trials